Pim Dekker
Research Subjects
Pim Dekker has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Erwin Birnie
Diabeter Netherlands, Centre for Pediatric and Adult Diabetes Care and Research Rotterdam The Netherlands
5 shared publications Henk-Jan Aanstoot
Diabeter, Center for Pediatric and Adult Diabetes Care and Research
5 shared publications- Bruce H. R. Wolffenbuttel
University of Groningen, University Medical Center Groningen
4 shared publications - Charlotte E. Vollenbrock
University Medical Center Groningen, Endocrinology, University of Groningen, Groningen, Groningen, The Netherlands
4 shared publications Christine Fransman
Diabeter, Center for Pediatric and Adult Diabetes Care and Research
4 shared publications- Dick Mul
Diabeter Netherlands, Center for Type 1 Diabetes Care and Research, Rotterdam, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by Frontiers Media SA in Frontiers in Clinical Diabetes and Healthcare
- Vol. 7, 1729632
Exploring feasible ways of person-reported outcome measurement in routine type 1 diabetes care: a protocol for the Diabeter-PROM study
Background: Psychosocial person-reported outcome measurements (PROMs) may assist monitoring, screening and support in routine care for people with type 1 diabetes (PWDs). However, recommended PROM sets are either too limited in covered domains, too time-consuming, or too general to fit type 1 diabetes (T1D) clinical practice. We propose an alternative approach to PROM assessment in routine daily T1D care (Diabeter-PROM study) that is maximally relevant and minimally burdensome for PWDs and healthcare professionals (HCPs). We identify single index questions indicating the need for more in-depth assessment, thereby aligning total assessment length more closely with individual needs. Methods: Scientist-practitioners identified twelve key psychosocial domains based on literature review, clinical experience and discussion with PWDs: general quality of life, mood, anxiety, diabetes-specific worries, impact, disturbed eating behaviour, self-efficacy, self-esteem, social support/interaction, resiliency, stigma and satisfaction with care. These domains will be divided over three observational mixed-method sub-studies. Through purposive-sampled interviews and panels, HCPs and PWDs (> 10 per sub study) co-determine candidate index questions for each domain. These are then included in three separate cross sectional questionnaire batteries with existing PROMs. Each will be completed by ≥200 PWDs from our clinic. Per domain, the optimal index question and most informative in-depth item set are determined using statistics (test characteristics, item response) and clinical interpretation. Discussion: We describe the exploration of an alternative way of PROM assessments, adapted to use in regular T1D care. After determining the most suitable index questions, we will apply this system in our daily diabetes practice, taking end-user needs into account and facilitating sustainable PROM implementation in routine care.
- 16 February 2026
- Published by Frontiers Media SA in Frontiers in Clinical Diabetes and Healthcare
- Vol. 7, 1729632
Open AccessExploring feasible ways of person-reported outcome measurement in routine type 1 diabetes care: a protocol for the Diabeter-PROM study
Background: Psychosocial person-reported outcome measurements (PROMs) may assist monitoring, screening and support in routine care for people with type 1 diabetes (PWDs). However, recommended PROM sets are either too limited in covered domains, too time-consuming, or too general to fit type 1 diabetes (T1D) clinical practice. We propose an alternative approach to PROM assessment in routine daily T1D care (Diabeter-PROM study) that is maximally relevant and minimally burdensome for PWDs and healthcare professionals (HCPs). We identify single index questions indicating the need for more in-depth assessment, thereby aligning total assessment length more closely with individual needs. Methods: Scientist-practitioners identified twelve key psychosocial domains based on literature review, clinical experience and discussion with PWDs: general quality of life, mood, anxiety, diabetes-specific worries, impact, disturbed eating behaviour, self-efficacy, self-esteem, social support/interaction, resiliency, stigma and satisfaction with care. These domains will be divided over three observational mixed-method sub-studies. Through purposive-sampled interviews and panels, HCPs and PWDs (> 10 per sub study) co-determine candidate index questions for each domain. These are then included in three separate cross sectional questionnaire batteries with existing PROMs. Each will be completed by ≥200 PWDs from our clinic. Per domain, the optimal index question and most informative in-depth item set are determined using statistics (test characteristics, item response) and clinical interpretation. Discussion: We describe the exploration of an alternative way of PROM assessments, adapted to use in regular T1D care. After determining the most suitable index questions, we will apply this system in our daily diabetes practice, taking end-user needs into account and facilitating sustainable PROM implementation in routine care.
- Open Access
- 28 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 2473-2476
What is the impact of an advanced hybrid closed‐loop system on weight control among people with type 1 diabetes?
- 28 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 2473-2476
Open AccessWhat is the impact of an advanced hybrid closed‐loop system on weight control among people with type 1 diabetes?
- Open Access
- 31 March 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-8
Evaluating cloudcare, a population health management system, in persons with type 1 diabetes: an observational study
Background: Innovations in diabetes technology have consistently improved outcomes of persons with type1 diabetes (PWDs). However, the volumes of data that these technologies yield require different workflows to alleviate healthcare professionals’ (HCPs) workload and prevent losing relevant data in between visits for interpretation and treatment adaptations. CloudCare is a population health management tool that continuously oversees data from groups of individual PWDs, based on remote monitoring, screening and triaging of individual PWDs. This study assesses the effect of CloudCare on treatment satisfaction of PWDs, HCPs’ workload and glycemic control of PWDs. Methods: We evaluated the 6-month follow-up outcomes as part of an ongoing prospective cohort study analyzing the effect of CloudCare. Adult PWDs diagnosed > 6 months before inclusion were enrolled. The primary outcome was the change in PWD treatment satisfaction (DTSQc). Secondary outcomes included the number and type of contacts between HCPs and PWDs, diabetes-related distress (PAID-5), and glycemic control. Results: In September 2024, 175 participants had baseline data available, with a median age of 29.9 years and a median diabetes duration of 17 years. Differences between baseline and 6 months could be calculated for 119 participants. After 6 months follow-up, the median increase in PWDs’ treatment satisfaction (DTSQc) was + 6.0 (IQR 2–11; p < 0.001). The number of face-to-face contacts per PWD per 3 months decreased from 0.85 at baseline to 0.34 (p < 0.001) at 6 months. Diabetes-related distress was significantly decreased at 3 months (p < 0.001) and at 6 months (p = 0.034), compared with baseline. Glucometrics did not significantly change, with a TIR of 79% at baseline and 78% after 6 months (p = 0.39), and a mean glucose management indicator (GMI) of 50 mmol/mol (6.7%) at all timepoints. Conclusions: In adult PWDs with good glycemic control, CloudCare decreases workload for HCPs, while increasing PWDs’ treatment satisfaction and maintaining excellent glycemic control during 6 months, showing this concept can be applied in modern diabetes care with high density data availability. Trial registration: Clinicaltrials.gov identifier: NCT05431140; registration date 21-6-2023.
- 31 March 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-8
Open AccessEvaluating cloudcare, a population health management system, in persons with type 1 diabetes: an observational study
Background: Innovations in diabetes technology have consistently improved outcomes of persons with type1 diabetes (PWDs). However, the volumes of data that these technologies yield require different workflows to alleviate healthcare professionals’ (HCPs) workload and prevent losing relevant data in between visits for interpretation and treatment adaptations. CloudCare is a population health management tool that continuously oversees data from groups of individual PWDs, based on remote monitoring, screening and triaging of individual PWDs. This study assesses the effect of CloudCare on treatment satisfaction of PWDs, HCPs’ workload and glycemic control of PWDs. Methods: We evaluated the 6-month follow-up outcomes as part of an ongoing prospective cohort study analyzing the effect of CloudCare. Adult PWDs diagnosed > 6 months before inclusion were enrolled. The primary outcome was the change in PWD treatment satisfaction (DTSQc). Secondary outcomes included the number and type of contacts between HCPs and PWDs, diabetes-related distress (PAID-5), and glycemic control. Results: In September 2024, 175 participants had baseline data available, with a median age of 29.9 years and a median diabetes duration of 17 years. Differences between baseline and 6 months could be calculated for 119 participants. After 6 months follow-up, the median increase in PWDs’ treatment satisfaction (DTSQc) was + 6.0 (IQR 2–11; p < 0.001). The number of face-to-face contacts per PWD per 3 months decreased from 0.85 at baseline to 0.34 (p < 0.001) at 6 months. Diabetes-related distress was significantly decreased at 3 months (p < 0.001) and at 6 months (p = 0.034), compared with baseline. Glucometrics did not significantly change, with a TIR of 79% at baseline and 78% after 6 months (p = 0.39), and a mean glucose management indicator (GMI) of 50 mmol/mol (6.7%) at all timepoints. Conclusions: In adult PWDs with good glycemic control, CloudCare decreases workload for HCPs, while increasing PWDs’ treatment satisfaction and maintaining excellent glycemic control during 6 months, showing this concept can be applied in modern diabetes care with high density data availability. Trial registration: Clinicaltrials.gov identifier: NCT05431140; registration date 21-6-2023.
- Open Access
- 28 October 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (3) , 1003-1014
Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care
Background: Complexity of glucose regulation in persons with type 1 diabetes (PWDs) necessitates increased automation of insulin delivery (AID). This study aimed to analyze real-world data over 12 months from PWDs who started using the MiniMed 780G (MM780G) advanced hybrid closed-loop (aHCL) AID system at the Diabeter clinic, focusing on glucometrics and clinical outcomes. Methods: Persons with type 1 diabetes switching to the MM780G system were included. Clinical data (e.g. HbA1c, previous modality) was collected from Diabeter’s electronic health records and glucometrics (time in range [TIR], time in tight range [TITR], time above range [TAR], time below range [TBR], glucose management indicator [GMI]) from CareLink Personal for a 12-month post-initiation period of the MM780G system. Outcomes were age-stratified, and the MM780G system was compared with previous use of older systems (MM640G and MM670G). Longitudinal changes in glucometrics were also evaluated. Results: A total of 481 PWDs were included, with 219 having prior pump/sensor system data and 334 having monthly longitudinal data. After MM780G initiation, HbA1c decreased from 7.6 to 7.1% ( P < .0001) and the percentage of PWDs with HbA1c 70% over 12 months. Age-stratified analysis showed consistent improvements of glycemic control across all age groups, with older participants achieving better outcomes. Participants using recommended system settings achieved better glycemic outcomes, reaching TIR up to 77% and TTIR up to 55%. Conclusions: Use of MM780G system results in significant and sustained glycemic improvements, consistent across age groups and irrespective of previous treatment modalities.
- 28 October 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (3) , 1003-1014
Open AccessTwelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care
Background: Complexity of glucose regulation in persons with type 1 diabetes (PWDs) necessitates increased automation of insulin delivery (AID). This study aimed to analyze real-world data over 12 months from PWDs who started using the MiniMed 780G (MM780G) advanced hybrid closed-loop (aHCL) AID system at the Diabeter clinic, focusing on glucometrics and clinical outcomes. Methods: Persons with type 1 diabetes switching to the MM780G system were included. Clinical data (e.g. HbA1c, previous modality) was collected from Diabeter’s electronic health records and glucometrics (time in range [TIR], time in tight range [TITR], time above range [TAR], time below range [TBR], glucose management indicator [GMI]) from CareLink Personal for a 12-month post-initiation period of the MM780G system. Outcomes were age-stratified, and the MM780G system was compared with previous use of older systems (MM640G and MM670G). Longitudinal changes in glucometrics were also evaluated. Results: A total of 481 PWDs were included, with 219 having prior pump/sensor system data and 334 having monthly longitudinal data. After MM780G initiation, HbA1c decreased from 7.6 to 7.1% ( P < .0001) and the percentage of PWDs with HbA1c 70% over 12 months. Age-stratified analysis showed consistent improvements of glycemic control across all age groups, with older participants achieving better outcomes. Participants using recommended system settings achieved better glycemic outcomes, reaching TIR up to 77% and TTIR up to 55%. Conclusions: Use of MM780G system results in significant and sustained glycemic improvements, consistent across age groups and irrespective of previous treatment modalities.
- Open Access
Cohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study—a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Participants Data and samples were collected in two subsets. A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration from four Dutch Diabetes clinics between 2016 and 2021 (median age 32 years; median diabetes duration 12 years; 59% female; mean glycated haemoglobin (HbA1c) 61 mmol/mol (7.7%); 61% on insulin pump; 23% on continuous glucose monitoring (CGM)). Physical assessments were performed, blood and urine samples were collected, and participants completed questionnaires. A subgroup of participants underwent mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. A second cross-sectional cohort included participants with ≥35 years of T1D duration (currently n=160; median age 64 years; median diabetes duration 45 years; 45% female; mean HbA1c 58 mmol/mol (7.4%); 51% on insulin pump; 83% on CGM), recruited from five centres and measurements, samples and 5-year retrospective data were collected. Findings to date Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 min and 120 min showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Fasting residual C-peptide secretion is associated with a decreased risk of impaired awareness of hypoglycaemia. Future plans Research groups are invited to consider the use of these data and the sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNAs, metabolomics and gene expression data, combined with glucometrics, anthropometric and clinical data, and additional markers of residual beta-cell function. Trial registration number NCT04977635.
Open AccessCohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study—a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Participants Data and samples were collected in two subsets. A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration from four Dutch Diabetes clinics between 2016 and 2021 (median age 32 years; median diabetes duration 12 years; 59% female; mean glycated haemoglobin (HbA1c) 61 mmol/mol (7.7%); 61% on insulin pump; 23% on continuous glucose monitoring (CGM)). Physical assessments were performed, blood and urine samples were collected, and participants completed questionnaires. A subgroup of participants underwent mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. A second cross-sectional cohort included participants with ≥35 years of T1D duration (currently n=160; median age 64 years; median diabetes duration 45 years; 45% female; mean HbA1c 58 mmol/mol (7.4%); 51% on insulin pump; 83% on CGM), recruited from five centres and measurements, samples and 5-year retrospective data were collected. Findings to date Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 min and 120 min showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Fasting residual C-peptide secretion is associated with a decreased risk of impaired awareness of hypoglycaemia. Future plans Research groups are invited to consider the use of these data and the sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNAs, metabolomics and gene expression data, combined with glucometrics, anthropometric and clinical data, and additional markers of residual beta-cell function. Trial registration number NCT04977635.
- Open Access
Cohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study – a prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Data and samples are available for new studies and collaborations. Participants Data- and samples were collected in two subsets. 1) A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration was recruited from four Dutch Diabetes clinics between June 2016 and March 2021. At baseline and 1- and 2-year follow-up visits, physical assessments were performed, and blood and urine samples were collected. Participants completed questionnaires about diabetes-related problems, quality of life, neuropathy and impaired awareness of hypoglycaemia at baseline and at the last follow-up visit. A subgroup of participants underwent mixed-meal tolerance tests (MMTT) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. 2) A second cross-sectional cohort, aiming to include 200 participants aged ≥18 years with ≥35 years T1D duration, was recruited from 7 centres, collecting measurements and samples plus 5-year retrospective data. Findings to date Fasting residual C-peptide secretion associated with decreased risk of impaired awareness of hypoglycaemia. Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 minutes and 120 minutes showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Future plans Research groups are invited to consider the use of this data and sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNA’s, metabolomics and gene expression data, combined with glucometrics, anthropometric/clinical data and additional markers of residual beta-cell function. Strengths - The Biomarker cohort is a large longitudinal prospective cohort study with three time points, collecting biosamples and clinical data from participants with well-established and long-standing type 1 diabetes (≥5 years). - A subgroup with detailed clinical data underwent MMTT tests at two timepoints allowing further residual beta-cell marker studies. - The Biomarker and Long-Term type 1 Diabetes cohorts represent a “real-world” population, also including participants from non-academic/-specialised centres. Limitations - Despite the fact that data and biosamples were collected from more than 600 participants, this number may be too low for (sub) stratification of the data (e.g. insulin delivery modality, different treating centres and therapies etc.). - In the prospective group there was a relatively high dropout rate of 25% after 2 years, largely affected by the Covid-19 outbreak.
Open AccessCohort profile: the ‘Biomarkers of heterogeneity in type 1 diabetes’ study – a prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Data and samples are available for new studies and collaborations. Participants Data- and samples were collected in two subsets. 1) A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration was recruited from four Dutch Diabetes clinics between June 2016 and March 2021. At baseline and 1- and 2-year follow-up visits, physical assessments were performed, and blood and urine samples were collected. Participants completed questionnaires about diabetes-related problems, quality of life, neuropathy and impaired awareness of hypoglycaemia at baseline and at the last follow-up visit. A subgroup of participants underwent mixed-meal tolerance tests (MMTT) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. 2) A second cross-sectional cohort, aiming to include 200 participants aged ≥18 years with ≥35 years T1D duration, was recruited from 7 centres, collecting measurements and samples plus 5-year retrospective data. Findings to date Fasting residual C-peptide secretion associated with decreased risk of impaired awareness of hypoglycaemia. Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 minutes and 120 minutes showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Future plans Research groups are invited to consider the use of this data and sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNA’s, metabolomics and gene expression data, combined with glucometrics, anthropometric/clinical data and additional markers of residual beta-cell function. Strengths - The Biomarker cohort is a large longitudinal prospective cohort study with three time points, collecting biosamples and clinical data from participants with well-established and long-standing type 1 diabetes (≥5 years). - A subgroup with detailed clinical data underwent MMTT tests at two timepoints allowing further residual beta-cell marker studies. - The Biomarker and Long-Term type 1 Diabetes cohorts represent a “real-world” population, also including participants from non-academic/-specialised centres. Limitations - Despite the fact that data and biosamples were collected from more than 600 participants, this number may be too low for (sub) stratification of the data (e.g. insulin delivery modality, different treating centres and therapies etc.). - In the prospective group there was a relatively high dropout rate of 25% after 2 years, largely affected by the Covid-19 outbreak.
- 31 July 2023
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 25 (8) , 559-570
Prevalence of and Reasons for Discontinuation of Continuous Subcutaneous Insulin Infusion in People with Type 1 Diabetes: A Systematic Review
The introduction of continuous subcutaneous insulin infusion in clinical care has led to more optimal glycemic and quality-of-life outcomes, compared with multiple daily injections (MDI). Despite this, some insulin pump users revert back to MDI. The aim of this review was to include the most recent rates of insulin pump discontinuation among people with type 1 diabetes and to identify reasons for and factors associated with discontinuation. A systematic literature search was conducted using the Embase.com, MEDLINE (via OVID), PsycINFO, and CINAHL databases. Titles and abstracts of eligible publications were screened, and baseline characteristics of the included studies were extracted, as were variables in the context of insulin pump use. Data were synthesized into themes: indications for insulin pump initiation, persons with type 1 diabetes (PWD)-reported reasons for, and factors associated with insulin pump discontinuation. A total of 826 eligible publications were identified and 67 were included. Discontinuation percentages ranged from 0% to 30% (median 7%). The most frequently mentioned reasons for discontinuation were wear-related issues (e.g., device attached to the body, interference with daily activities, discomfort, affected body image). Related factors included hemoglobin A1c (HbA1c) (17%), issues with following treatment recommendations (14%), age (11%), gender (9%), side effects (7%), and comorbidity- and complication-related factors (6%). Despite many developments in insulin pump technology, discontinuation rates and PWD-reported reasons for and factors associated with insulin pump discontinuation in more recent studies were comparable to earlier reviews/meta-analyses. Continuation of insulin pump treatment depends on a knowledgeable and willing health care provider (HCP) team and a close match with PWDs' wishes and needs.
- 31 July 2023
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 25 (8) , 559-570
Prevalence of and Reasons for Discontinuation of Continuous Subcutaneous Insulin Infusion in People with Type 1 Diabetes: A Systematic Review
The introduction of continuous subcutaneous insulin infusion in clinical care has led to more optimal glycemic and quality-of-life outcomes, compared with multiple daily injections (MDI). Despite this, some insulin pump users revert back to MDI. The aim of this review was to include the most recent rates of insulin pump discontinuation among people with type 1 diabetes and to identify reasons for and factors associated with discontinuation. A systematic literature search was conducted using the Embase.com, MEDLINE (via OVID), PsycINFO, and CINAHL databases. Titles and abstracts of eligible publications were screened, and baseline characteristics of the included studies were extracted, as were variables in the context of insulin pump use. Data were synthesized into themes: indications for insulin pump initiation, persons with type 1 diabetes (PWD)-reported reasons for, and factors associated with insulin pump discontinuation. A total of 826 eligible publications were identified and 67 were included. Discontinuation percentages ranged from 0% to 30% (median 7%). The most frequently mentioned reasons for discontinuation were wear-related issues (e.g., device attached to the body, interference with daily activities, discomfort, affected body image). Related factors included hemoglobin A1c (HbA1c) (17%), issues with following treatment recommendations (14%), age (11%), gender (9%), side effects (7%), and comorbidity- and complication-related factors (6%). Despite many developments in insulin pump technology, discontinuation rates and PWD-reported reasons for and factors associated with insulin pump discontinuation in more recent studies were comparable to earlier reviews/meta-analyses. Continuation of insulin pump treatment depends on a knowledgeable and willing health care provider (HCP) team and a close match with PWDs' wishes and needs.
- Open Access
- 4 December 2022
- Published by Wiley in Diabetic Medicine
- Vol. 40 (2)
Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus
Aims: This study aims to evaluate the stability of C‐peptide over time and to compare fasting C‐peptide and C‐peptide response after mixed‐meal tolerance test (MMTT) at T90 or T120 with C‐peptide area under the curve (AUC) in long‐standing type 1 diabetes.Methods: We included 607 type 1 diabetes individuals with diabetes duration >5 years. C‐peptide concentrations (ultrasensitive assay) were collected in the fasting state, and in a subpopulation after MMTT (T0, just prior to, T30‐T60‐T90‐T120, 30–120 min after ingestion of mixed‐meal) (n = 168). Fasting C‐peptide concentrations (in n = 535) at Year 0 and Year 1 were compared. The clinical determinants associated with residual C‐peptide secretion and the correspondence of C‐peptide at MMTT T90 / T120 and total AUC were assessed.Results: A total of 153 participants (25%) had detectable fasting serum C‐peptide (i.e ≥ 3.8 pmol/L). Fasting C‐peptide was significantly lower at Year 1 (p < 0.001, effect size = −0.16). Participants with higher fasting C‐peptide had a higher age at diagnosis and shorter disease duration and were less frequently insulin pump users. Overall, 109 of 168 (65%) participants had both non‐detectable fasting and post‐meal serum C‐peptide concentrations. The T90 and T120 C‐peptide values at MMTT were concordant with total AUC. In 17 (10%) individuals, C‐peptide was only detectable at MMTT and not in the fasting state.Conclusions: Stimulated C‐peptide was detectable in an additional 10% of individuals compared with fasting in individuals with >5 years of diabetes duration. T90 and T120 MMTT measurements showed good concordance with the MMTT total AUC. Overall, there was a decrease of C‐peptide at 1‐year follow‐up.
- 4 December 2022
- Published by Wiley in Diabetic Medicine
- Vol. 40 (2)
Open AccessFasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus
Aims: This study aims to evaluate the stability of C‐peptide over time and to compare fasting C‐peptide and C‐peptide response after mixed‐meal tolerance test (MMTT) at T90 or T120 with C‐peptide area under the curve (AUC) in long‐standing type 1 diabetes.Methods: We included 607 type 1 diabetes individuals with diabetes duration >5 years. C‐peptide concentrations (ultrasensitive assay) were collected in the fasting state, and in a subpopulation after MMTT (T0, just prior to, T30‐T60‐T90‐T120, 30–120 min after ingestion of mixed‐meal) (n = 168). Fasting C‐peptide concentrations (in n = 535) at Year 0 and Year 1 were compared. The clinical determinants associated with residual C‐peptide secretion and the correspondence of C‐peptide at MMTT T90 / T120 and total AUC were assessed.Results: A total of 153 participants (25%) had detectable fasting serum C‐peptide (i.e ≥ 3.8 pmol/L). Fasting C‐peptide was significantly lower at Year 1 (p < 0.001, effect size = −0.16). Participants with higher fasting C‐peptide had a higher age at diagnosis and shorter disease duration and were less frequently insulin pump users. Overall, 109 of 168 (65%) participants had both non‐detectable fasting and post‐meal serum C‐peptide concentrations. The T90 and T120 C‐peptide values at MMTT were concordant with total AUC. In 17 (10%) individuals, C‐peptide was only detectable at MMTT and not in the fasting state.Conclusions: Stimulated C‐peptide was detectable in an additional 10% of individuals compared with fasting in individuals with >5 years of diabetes duration. T90 and T120 MMTT measurements showed good concordance with the MMTT total AUC. Overall, there was a decrease of C‐peptide at 1‐year follow‐up.
- Open Access
- 21 November 2022
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 130 (11) , 740-750
Effects of Peri-Conception and Pregnancy Glycemic Variability on Pregnancy and Perinatal Complications in Type 1 Diabetes: A Pilot Study
Background: Not much is known about the effects of glycemic variability (GV) during the pre- and periconception period on pregnancy/perinatal complications. GV could potentially contribute to identification of high-risk pregnancies in women with type 1 diabetes. Methods: An explorative retrospective cohort study was conducted between January 2014 and May 2019. Glucose data were retrieved from electronic patient charts. Pre-/periconceptional GV and GV during all three trimesters was expressed as mean glucose, standard deviation (SD), Coefficient of Variation (CV), High Blood Glucose Index (HBGI), Low Blood Glucose Index (LBGI) and Average Daily Risk Range (ADRR). Maternal and neonatal complications were summarized using a composite total complication score. Binary logistic regression analyses were conducted to assess correlations between the GV measures and a total complication score >3, a maternal complication score >1 and a neonatal complication score >1. Results: Of 63 eligible women, 29 women (38 pregnancies) were included. Women in the group with a total complication score >3 had a significantly higher ADRR at conception (OR 1.1, CI 1.0–1.2, p=0.048). No statistically significant correlation between complication score and any other GV metric besides the ADRR were found. Although not significant, in the group with a complication score >3, odds ratios >1 were found for SD in trimester 1 (OR 1.6, CI 0.6–4.5, p=0.357) and trimester 2 (OR 1.8, CI 0.5–6.2, p=0.376). Conclusions: Presence of a positive association between GV and pregnancy and perinatal complications depends on which pregnancy period is assessed and the GV metrics that are used. Received: 12 May 2021 Accepted after revision: 07 March 2022 Publication Date: 14 March 2022 (online) © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 21 November 2022
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 130 (11) , 740-750
Open AccessEffects of Peri-Conception and Pregnancy Glycemic Variability on Pregnancy and Perinatal Complications in Type 1 Diabetes: A Pilot Study
Background: Not much is known about the effects of glycemic variability (GV) during the pre- and periconception period on pregnancy/perinatal complications. GV could potentially contribute to identification of high-risk pregnancies in women with type 1 diabetes. Methods: An explorative retrospective cohort study was conducted between January 2014 and May 2019. Glucose data were retrieved from electronic patient charts. Pre-/periconceptional GV and GV during all three trimesters was expressed as mean glucose, standard deviation (SD), Coefficient of Variation (CV), High Blood Glucose Index (HBGI), Low Blood Glucose Index (LBGI) and Average Daily Risk Range (ADRR). Maternal and neonatal complications were summarized using a composite total complication score. Binary logistic regression analyses were conducted to assess correlations between the GV measures and a total complication score >3, a maternal complication score >1 and a neonatal complication score >1. Results: Of 63 eligible women, 29 women (38 pregnancies) were included. Women in the group with a total complication score >3 had a significantly higher ADRR at conception (OR 1.1, CI 1.0–1.2, p=0.048). No statistically significant correlation between complication score and any other GV metric besides the ADRR were found. Although not significant, in the group with a complication score >3, odds ratios >1 were found for SD in trimester 1 (OR 1.6, CI 0.6–4.5, p=0.357) and trimester 2 (OR 1.8, CI 0.5–6.2, p=0.376). Conclusions: Presence of a positive association between GV and pregnancy and perinatal complications depends on which pregnancy period is assessed and the GV metrics that are used. Received: 12 May 2021 Accepted after revision: 07 March 2022 Publication Date: 14 March 2022 (online) © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 6 January 2022
- Published by Wiley in Diabetic Medicine
- Vol. 39 (5) , e14785
How low is really low? Comparison of two C‐peptide assays to establish residual C‐peptide production in type 1 diabetes
Introduction: C‐peptide is an important marker to assess residual insulin production in individuals with type 1 diabetes (T1D). The accuracy and detection limits of C‐peptide assays are important to detect C‐peptide microsecretion and to reliably observe changes over time in these people. We compared and verified two commercially available assays able to measure C‐peptide in the picomolar range.Methods: The ultrasensitive Mercodia enzyme‐linked immunosorbent C‐peptide assay (ELISA) was compared with the Beckman immunoradiometric assay (IRMA) for C‐peptide, assessing reproducibility (coefficient of variation [CV]), limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ).Results: For both assays within‐run and between‐run variation were high at the low (around the detection limit) C‐peptide concentration range, with CVs of around 40%. LoB values for the ultrasensitive ELISA and the IRMA were 1.3 and 0.16 pmol/L respectively. LoD values were 2.4 and 0.54 pmol/L respectively. LoQ values were 9.7 and 3.8 pmol/L respectively. Only the IRMA met the specifications claimed by the manufacturer.Conclusions: The IRMA provided the lowest threshold for quantification of serum C‐peptide. LoQ of commercially available assays should be established in‐house before applying them in research studies and clinical trials in which low C‐peptide levels have clinical or scientific relevance.
- 6 January 2022
- Published by Wiley in Diabetic Medicine
- Vol. 39 (5) , e14785
Open AccessHow low is really low? Comparison of two C‐peptide assays to establish residual C‐peptide production in type 1 diabetes
Introduction: C‐peptide is an important marker to assess residual insulin production in individuals with type 1 diabetes (T1D). The accuracy and detection limits of C‐peptide assays are important to detect C‐peptide microsecretion and to reliably observe changes over time in these people. We compared and verified two commercially available assays able to measure C‐peptide in the picomolar range.Methods: The ultrasensitive Mercodia enzyme‐linked immunosorbent C‐peptide assay (ELISA) was compared with the Beckman immunoradiometric assay (IRMA) for C‐peptide, assessing reproducibility (coefficient of variation [CV]), limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ).Results: For both assays within‐run and between‐run variation were high at the low (around the detection limit) C‐peptide concentration range, with CVs of around 40%. LoB values for the ultrasensitive ELISA and the IRMA were 1.3 and 0.16 pmol/L respectively. LoD values were 2.4 and 0.54 pmol/L respectively. LoQ values were 9.7 and 3.8 pmol/L respectively. Only the IRMA met the specifications claimed by the manufacturer.Conclusions: The IRMA provided the lowest threshold for quantification of serum C‐peptide. LoQ of commercially available assays should be established in‐house before applying them in research studies and clinical trials in which low C‐peptide levels have clinical or scientific relevance.